MINDBIO Aktie

 

  90th participant enrolled in landmark clinical trial in patients with Major Depressive Disorder  Targets October 2025 for initial results presentation  Vancouver, British Columbia – TheNewswire - June 18, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharma/biotechnology company dedicated to developing novel and effective mental health treatments, is pleased to announce the enrolment of the 90th and final participant in its landmark Phase 2B clinical trial evaluating MB22001 for Major Depressive Disorder (MDD). This Phase 2B trial, in 90 patients with Major Depressive Disorder is an 8-week triple blind, double dummy, active placebo-controlled trial. The sub-hallucinogenic microdoses administered in the form of MB22001 in this innovative trial design, allow patients to seamlessly integrate the treatment into their daily lives, offering a practical, convenient and commercially scalable alternative to clinic-based, high-...

Vancouver, British Columbia – TheNewswire – June 11, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharma/biotechnology company dedicated to developing novel and effective mental health treatments, is pleased to announce the enrolment of the 85th participant in its landmark Phase 2B clinical trial evaluating MB22001 for Major Depressive Disorder (MDD). MB22001, MindBio's proprietary, titratable formulation of lysergic acid diethylamide (LSD) designed for safely monitored, take-home microdosing, has shown a robust safety, adherence, and tolerability profile across thousands of self-administered doses under randomized controlled conditions. This Phase 2B trial, in 90 patients with Major Depressive Disorder is an 8-week triple blind, double dummy, active placebo-controlled trial. The sub-hallucinogenic microdoses administered in this innovative trial design, allow patients to seamlessly integrate the treatment into their daily...

MindBio debuts app.booze-ai.com to investors in Silicon Valley Vancouver, British Columbia – TheNewswire - June 3, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharma/biotechnology company has today launched Booze AI, in Silicon Valley, debuting the world's first AI-driven, voice-activated blood alcohol concentration (BAC) estimator for use on smartphones, tablets and computers to 150 institutional investors. This cutting-edge technology empowers users to monitor an estimate of their alcohol levels on the go, simply by talking to their smartphone and completing behavioural tasks, the novel software application delivering real-time insights to promote responsible drinking and prevent impaired driving. app.booze-ai.com Click Image To View Full Size The novel intellectual property originates from MindBio's drug trials and a range of studies the Company has conducted analysing the effects of drugs and alcohol intoxication on spe...

  Company completes final development of Booze AI software  Booze AI predicts and estimates blood alcohol concentration using Speech and AI tools  Convenient software application for use on a Smartphone or Computer   Informational and educational tool with strong drink driving deterrence objective  Vancouver, British Columbia – TheNewswire - May 26, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharma/biotechnology company dedicated to developing novel and effective mental health treatments, is pleased to announce the Company has completed development of the Booze AI software application and is preparing for first sales launch.   Booze AI is the world's first voice activated and AI powered blood alcohol estimator over a smartphone.  Booze AI users, after submitting baseline information, simply follow a few voice prompts and tasks on their smartphone, to receive an estimate of their Blood Alcohol Concentration (BAC)....

  A Brighter Future for Mental Health  CSE: MBI Vancouver, British Columbia – May 19, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel and effective mental health treatments, is pleased to announce the enrolment of the 80th participant in its landmark Phase 2B clinical trial evaluating MB22001 for Major Depressive Disorder (MDD). This milestone underscores MindBio's enduring commitment to developing innovative, accessible, affordable and commercially scalable treatments to address the global mental health crisis. MB22001, MindBio's proprietary, titratable formulation of lysergic acid diethylamide (LSD) designed for safely monitored, take-home microdosing, has shown a robust safety, adherence, and tolerability profile across thousands of self-administered doses under randomized controlled conditions. This Phase 2B trial, in 90 patients with Major Depressive Disorder is an 8-w...

Vancouver, British Columbia, May 19, 2025 – MindBio Therapeutics Corp. (the “Company” or “MindBio”) (CSE:MBIO) is pleased to announce that it has completed its previously announced (May 12, 2025) non-brokered private placement and debt settlements effective May 19, 2025.   Private Placement   The Company completed a non-brokered private placement (the “Offering”) of 9,292,038 common shares of the Company (the “Shares”) at a price of $0.010 per Share for aggregate gross proceeds of $92,920. The proceeds from the Offering are expected to be used for working capital and general corporate purposes. All Shares issued in connection with the Offering are subject to restrictions on resale until September 20, 2025 in accordance with applicable securities laws.     The Company paid a cash finder's fee of $7,434 in connection with the Offering to eligible finders in accordance with the policies of the CSE and applicable securities laws. Such finders fees represented a cash commission of 8% o...

Vancouver, British Columbia – TheNewswire - May 12, 2025 – MindBio Therapeutics Corp. (the “Company” or “MindBio”) (Frankfurt: WF6), (CSE:MBIO), a clinical stage biopharma company targeting depressive illnesses currently in multiple late stage Phase 2B clinical trials is pleased to announce that as a result of strong support from its lenders, shareholders and investors, it has initiated a proposed package of financing and debt settlements which should position the Company well to embrace the opportunities in front of it in 2025.   Private Placement   The Company recently completed a private placement for gross proceeds of $174,783 and is now announcing a non-brokered private placement (the “Offering”) of up to 11,000,000 common shares of the Company (the “Shares”) at a price of $0.010 per Share for aggregate gross proceeds of up to $110,000. The proceeds from the Offering are expected to be used for working capital and general corporate purposes.   The Offering is expected to close...

Vancouver, British Columbia – TheNewswire - May 7, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a pioneering clinical-stage biopharmaceutical company dedicated to developing novel and effective mental health treatments, has today issued Restricted Stock Units (RSUs) to certain directors and individuals that work for the Company. On May 2, 2025, the Company's Board of Directors approved the issuance of an aggregate of 8,000,000 Restricted Stock Units ("RSUs") to two of its independent directors in lieu of cash compensation for their service on the Board. A further 27,004,730 RSUs were issued to twelve individual staff and contractors of the Company in lieu of cash compensation.  The RSUs vest upon the occurrence of a "Vesting Event" as defined in the applicable RSU grant agreements. Upon vesting, one share in the capital of the Company will be issued for each vested RSU held. “Securing the commitment and services of talent...

Vancouver, British Columbia, April 24, 2025 – TheNewswire - MindBio Therapeutics Corp. (the “Company” or “MindBio”) (CSE:MBIO) is pleased to announce that it has completed its previously announced (April 11, 2025) non-brokered private placement and debt settlements effective April 23, 2025.   Private Placement   The Company completed a non-brokered private placement (the “Offering”) of 15,889,329 common shares of the Company (the “Shares”) at a price of $0.011 per Share for aggregate gross proceeds of $174,783. The proceeds from the Offering are expected to be used for working capital and general corporate purposes. All Shares issued in connection with the Offering are subject to restrictions on resale until August 24, 2025 in accordance with applicable securities laws.     The Company paid a cash finder's fee of $ 13,982 in connection with the Offering to eligible finders in accordance with the policies of the CSE and applicable securities laws. Such finders fees represented a ca...

   As a result of a review by the British Columbia Securities Commission (the “BCSC”), we are issuing the following press release to clarify our disclosure. Vancouver, British Columbia – TheNewswire - April 15, 2025 – MindBio Therapeutics Corp. (the “Company” or “MindBio”) (CSE: MBIO; Frankfurt: WF6) announces that, pursuant to Section 11.5 of National Instrument 51-102 - Continuous Disclosure Obligations, and as a result of a review by the BCSC, it has amended and refiled its interim management's discussion and analysis (the “Amended Interim MD&A”) for the period ended December 31, 2024 and its annual MD&A for the year ended June 30, 2024 (the “Amended MD&A” and together with the Amended Interim MD&A, the “Amended MD&As”) to clarify its disclosure. The Amended MD&As provide revised and updated disclosure respecting, among other things, the Company's overall performance, operations, liquidity and capital resources, investor loans, management compens...

Vancouver, British Columbia – TheNewswire - April 11, 2025 – MindBio Therapeutics Corp. (the “Company” or “MindBio”) (Frankfurt: WF6), (CSE:MBIO), a clinical stage biopharma company targeting depressive illnesses currently in multiple late stage Phase 2B clinical trials is pleased to announce that as a result of strong support from its lenders, shareholders and other creditors and investors, it has initiated a proposed package of financing and debt settlements which should position the Company well to embrace the opportunities in front of it in 2025.   Private Placement   The Company is announcing a non-brokered private placement (the “Offering”) of up to 15,454,546 common shares of the Company (the “Shares”) at a price of $0.011 per Share for aggregate gross proceeds of up to $170,000. The proceeds from the Offering are expected to be used for working capital and general corporate purposes.   The Offering is expected to close on or around April 18, 2025, and is conditional on the ...

Vancouver, British Columbia – TheNewswire - 7 April, 2025 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “Company” or “MindBio”), is a clinical stage biopharmaceutical company targeting depressive illnesses currently dosing in multiple Phase 2B clinical trials.   The Company today has issued 3,428,571 common share purchase warrants (the “Warrants”), to Haywood Securities in connection with the completion of strategic investment and advisory services to the Company.  The Warrants are exercisable until 4:30pm on 6 April 2026, and are exercisable at a price per share of CAD$0.05, (the “Exercise Price”). We invite you to join us in support of creating a brighter future for mental health. For further information, please contact:   Justin Hanka, Chief Executive Officer 61 433140886 justin@mindbiotherapeutics.com   Media Inquiries Kristina Spionjak pr@hlthcommunications.com   About MindBio Therapeutics   MindBio is a leading biotech/biopharma company focused on creati...

  Vancouver, British Columbia – TheNewswire - April 2, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company pioneering new treatments for mental health conditions announces that it has adopted a new equity incentive plan (the “New Plan”). The New Plan is a 20% rolling equity incentive plan that provides for the issuance of stock options, restricted share units (RSUs) and deferred share units (DSUs). The New Plan replaces the Company's old 20% fixed stock option plan (the “Old Plan”). In connection with the adoption of the New Plan, certain employees, consultants and directors of the Company agreed to cancel an aggregate of 26,592,250 stock options issued under the Old Plan. Stock options issued under the Old Plan that were not cancelled will be governed by the terms of the New Plan. The New Plan was approved by the directors of the Company on April 1, 2025.   We invite you to join us in support of cr...

Vancouver, British Columbia – TheNewswire - March 26, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company specialising in psychedelic microdosing, is pleased to announce the completion of its acquisition of all of the outstanding share capital of Life AI Corp. Pty. Ltd. (“Life AI”) pursuant to a definitive share purchase agreement (the “SPA”) dated effective March 24, 2025 (the “Acquisition”). The Acquisition closed on March 25, 2025. As previously announced on January 21, 2025, Life AI has intellectual property in the form of technology, and its most advanced technology which is still in development is a smartphone-based application (the “Booze AI App”) used for alcohol intoxication detection. The Booze AI App will provide an estimate of blood alcohol concentration based on an analysis of a user's speech and other biophysical information.  For more information on the Booze AI App, visit www.b...

  A Brighter Future for Mental Health  CSE: MBIO     Vancouver, British Columbia – February 14, 2025 – MindBio Therapeutics Corp. (the “Company” or “MindBio”) (CSE: MBIO; Frankfurt: WF6) announces that, pursuant to Section 11.5 of National Instrument 51-102 - Continuous Disclosure Obligations, and as a result of a review by the British Columbia Securities Commission, it plans to amend and refile its interim management's discussion and analysis ("MD&A") for the period ended December 31, 2024 and its annual MD&A for the year ended June 30, 2024 (the “MD&A”, and as amended, the “Amended MD&A”) to clarify its disclosure. The Amended MD&A is expected to provide revised and updated disclosure respecting, among other things, the Company's overall performance, operations, liquidity and capital resources, investor loans, management compensation and related party transactions. The Company will also refile its interim financial statement and related officer's...

Vancouver, British Columbia – TheNewswire - 28 January, 2025 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “Company” or “MindBio”), is a clinical stage biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines to treat depressive disorders.  The Company is delighted to report the outcome of a mandatory independent safety audit of its two currently dosing Phase 2B clinical trials. MindBio is currently dosing in two landmark clinical trials: Phase 2B trial in 90 patients with Major Depressive Disorder.  This is a triple blind, double dummy, active placebo-controlled trial.   Phase 2B trial in 40 patients with Advanced Stage Cancer, suffering from end of life distress, anxiety and depression.  This is a double blind, placebo-controlled trial of MB22001 as an adjunct to the use of Meaning Centred Psychotherapy, (the standard of mental health care in advance-stage cancer patients).  The Company is pleased to report the mandat...

Enters into Term Sheet to Acquire Life AI Corp Pty Ltd. Vancouver, British Columbia – TheNewswire - 21 January, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company specialising in psychedelic microdosing today announced a major discovery in the effect of psychedelic microdosing on patient's speech. The Company has discovered it can determine if a patient has dosed their medicine simply by analyzing their speech using advanced machine learning algorithms and artificial intelligence techniques. The speech discovery adds to a large repository of intellectual property,                             in the form of digital and AI related technologies the Company has developed as a protective and competitive moat around the dosing and administration of its lead candidate drug, MB22001. This intellectual property is used to monitor patient's adherence to dosage protocols, to deter misuse and immediately ...

  Vancouver, British Columbia – TheNewswire - 15 January, 2025 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “Company” or “MindBio”), is a clinical stage biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines to treat depressive disorders.  The Company is delighted to provide an update on clinical trial progress and technology developments.   MindBio is currently undertaking two landmark clinical trials due for completion in Q3 in 2025: Phase 2B trial in 90 patients with Major Depressive Disorder.  This is a triple blind, double dummy, active placebo-controlled trial.   Phase 2B trial in 40 patients with Advanced Stage Cancer, suffering from end of life distress, anxiety and depression.  This is a double blind, placebo-controlled trial of MB22001 as an adjunct to the use of Meaning Centred Psychotherapy, (the standard of mental health care in late stage cancer patients).  These trials are a world first and still the...

  Vancouver, British Columbia – December 11, 2024 – TheNewswire – MindBio Therapeutics Corp. (the “Company” or “MindBio”) (CSE: MBIO) (Frankfurt: WF6) wishes to provide an update to its shareholders on the impact of the strike by the Canadian Union of Postal Workers on the Company's ability to comply with its obligations to deliver shareholders its financial statements and related disclosure and proxy-related materials in respect of the Company's annual general meeting of shareholders scheduled to be held at Suite 2200, 885 West Georgia Street, Vancouver, British Columbia, Canada on the 18th day of December, 2024 at 2:00 p.m. (Vancouver time) (the “Meeting”) As a result of the strike, and pursuant to CSA Coordinated Blanket Order 51-931 Temporary Exemption from requirements in National Instrument 51-102 Continuous Disclosure Requirements and National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer to send certain proxy-related materials duri...

Vancouver, British Columbia – TheNewswire - December 9, 2024 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “Company” or “MindBio”), a leading clinical stage biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines, is pleased to announce successful completion of its previously announced private placement and proposed  issuance of listed securities in the Company. The Company is pleased to report it has completed a private placement, with funds raised from five private and institutional investors in the amount of $200,390 and 6,909,986 shares in the Company have been issued, (“Private Placement Shares”).  All Private Placement Shares will be subject to a hold period of four-months and one day from the date of issuance under applicable securities laws. The Company is also pleased to report that Riverfort Global Opportunities PCC Ltd has requested to convert CAD$50,000 of its loan to 1,000,000 MindBio shares, (“Shares”) ...